Drugmaker Amylin Draws Initial Bids

Biotechnology company Amylin Pharmaceuticals has drawn initial bids from drugmakers Merck & Co and Sanofi, Bloomberg News reported on Friday, citing anonymous sources.

The drugmakers made offers of at least $25 a share, which would value Amylin at more than $4 billion, the report said.

Sources have told Reuters that Amylin, which sells the diabetes drugs Byetta and Bydureon, started reaching out to potential buyers in April.

Merck declined to comment. Amylin and Sanofi were not immediately available to comment.

 

 

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.